By Ellen Foster Licking
April 28 should have been a day of celebration for Lexington, MA-based specialty pharma company AMAG Pharmaceuticals Inc. The...
AMAG Pharmaceuticals: Enough Irons In The Fire?
Demand for AMAG’s newly launched Feraheme has been robust but a changing reimbursement climate, especially in the dialysis market, complicates the product’s pricing strategy, and puts increased pressure on management to diversify via dealmaking.
More from Archive
More from In Vivo
• By
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
• By
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
• By
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.